FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Triamcinolone Hexacetonide Injectable suspension
Status: Currently in Shortage
»Date first posted: 05/04/2021
»Therapeutic Categories: Rheumatology

Medexus (Revised 05/06/2021)

Company Contact Information:
1-855-336-3322 Option 9

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Hexatrione 2% (triamcinolone hexacetonide) Injectable suspension, 20mg/ml, 2-mL glass ampoule (NDC 59137-570-01) Available Medexus in conjunction with FDA has initiated a temporary importation of Triamcinolone Hexacetonide (Hexatrione 2%) injectable suspension, to the U.S. market to address drug shortage. To place an order, please contact Medexus at 1-855-336-3322, Option # 9.

See Dear Healthcare Professional Letter

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English